ArticleCureus2026
A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is unusual for patients to have two or more concurrent hematologic malignancies. Simultaneous chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) are even more rare, and most reported cases are therapy-related. The incidence of cases of concurrent CLL and therapy-unrelated AML is even more rare at <1%. In this case report, we present a very rare case of a patient with concurrent CLL and therapy-unrelated myelodysplastic neoplasm (MDS) that transformed to AML. Peripheral flow cytometry and a bone marrow biopsy showed separate populations of myeloblasts and monoclonal B-lymphocytes. Both populations of cells were subjected to fluorescence in situ hybridization (FISH) testing and next-generation sequencing (NGS) which revealed an abnormal clone with the deletion of the long arm of chromosome seven (7q-) and RUNX1 and NF1 among myeloid cells, suggestive of adverse risk MDS-related AML. These cytogenetic findings were not observed among the lymphoid cells tested. The pathogenesis of concurrent CLL and de novo AML is unknown and requires further investigation. Given the differing cytogenetics among each cell population, the CLL and AML may have developed as separate clonal processes. With a further understanding of the pathogenic mechanism, this may influence the treatment decision-making process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.